摘要
目的：为了考察格列卫联合异基因造血干细胞移植治疗慢性粒细胞白血病（CML）对移植及造血重建的影响。方法：对6例CML患者于移植前6周开始口服格列卫600～800mg／d至移植当日，预处理方案是福达拉宾、白消安、环磷酰胺，人类白细胞抗原（HLA）不相合者加用抗胸腺细胞球蛋白。移植物抗宿主病防治采用环孢素A加短程甲氨喋呤加霉酚酸酯。结果：6例全部成功植入，WBC：〉0．5×10^9·L^-1平均为14．2d，PLT〉20×10^9·L^-1平均为15．6d。结论：CML患者移植前给予大剂量格列卫治疗不影响干细胞植入和骨髓造血的恢复。
Objective：To observe the influence of Gleevec administration on transplantation and hemopoietic reconstruction in patients with CML undergone allogeneic hematopoitic stem cell transplantation （Allo-HSCT）. Method：Six patients with chronic myeloid leukemia were given Gleevec 600～800 mg/d 6～8 weeks before transplantation until the tranplantation day, The conditioning regimen included Flu, busulfan and CTX, ATG was added in HLA mismatched patients. A combination of CsA, MMF and short-term MTX were given for GVHD prophylaxis. Result：Six patients were all successfully engrafed, Hematophosis reconstruction time was average 14.2 （9～22） days for WBC〉0.5×10^9 · L^-1 , 15.6（9～21） days for BPC〉20×10^9 · L^-1. Conclusion：Administration of high dosage Gleevec before transplantation has no effect on hemopoietic reconstruction in patients with CML.
出处
《临床血液学杂志》
CAS
2006年第1期7-9,共3页
Journal of Clinical Hematology
